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B Cell Synovitis and Clinical Phenotypes in Rheumatoid 
Arthritis: Relationship to Disease Stages and Drug Exposure
F. Rivellese,1  F. Humby,1  S. Bugatti,2 L. Fossati-Jimack,1  H. Rizvi,3 D. Lucchesi,1  G. Lliso-Ribera,1 
A. Nerviani,1 R. E. Hands,1 G. Giorli,1 B. Frias,1 G. Thorborn,1 E. Jaworska,1  C. John,1 K. Goldmann,1  
M. J. Lewis,1  A. Manzo,2 M. Bombardieri,1 C. Pitzalis,1 and the PEAC-R4RA Investigators
Objective. To define the relationship of synovial B cells to clinical phenotypes at different stages of disease 
evolution and drug exposure in rheumatoid arthritis (RA).
Methods. Synovial biopsy specimens and demographic and clinical data were collected from 2 RA cohorts 
(n = 329), one of patients with untreated early RA (n = 165) and one of patients with established RA with an inadequate 
response to tumor necrosis factor inhibitors (TNFi- IR; n = 164). Synovial tissue was subjected to hematoxylin and 
eosin and immunohistochemical staining and semiquantitative assessment for the degree of synovitis (on a scale of 
0–9) and of CD20+ B cell infiltrate (on a scale of 0–4). B cell scores were validated by digital image analysis and B cell 
lineage–specific transcript analysis (RNA- Seq) in the early RA (n = 91) and TNFi- IR (n = 127) cohorts. Semiquantitative 
CD20 scores were used to classify patients as B cell rich (≥2) or B cell poor (<2).
Results. Semiquantitative B cell scores correlated with digital image analysis quantitative measurements and B cell 
lineage–specific transcripts. B cell–rich synovitis was present in 35% of patients in the early RA cohort and 47.7% of 
patients in the TNFi- IR cohort (P = 0.025). B cell–rich patients showed higher levels of disease activity and seropositiv-
ity for rheumatoid factor and anti–citrullinated protein antibody in early RA but not in established RA, while significantly 
higher histologic synovitis scores in B cell–rich patients were demonstrated in both cohorts.
Conclusion. We describe a robust semiquantitative histologic B cell score that closely replicates the quantification 
of B cells by digital or molecular analyses. Our findings indicate an ongoing B cell–rich synovitis, which does not seem 
to be captured by standard clinimetric assessment, in a larger proportion of patients with established RA than early RA.
INTRODUCTION
The role of B cells in the pathogenesis of rheumatoid arthri­
tis (RA) is well recognized and has been reinforced by the estab­
lished efficacy of B cell–depleting treatments (1,2). B cells and B 
cell effector mechanisms are recognized as a central component 
of RA synovitis, through local autoantibody production (3,4), oste­
oclastogenesis/osteoclast activation (5,6), and immune complex–
mediated inflammatory responses (7,8). However, the degree of 
synovial B cell infiltrate is a highly variable phenomenon, ranging 
from complete absence to a dense distribution within organized 
infiltrates in up to 40% of patients (9–11) and as such has been 
examined as a potential source of predictive and prognostic bio­
markers in RA. Indeed, recent data from a large cohort of patients 
with untreated early RA have suggested that a B cell–rich lym­
phoid synovitis is associated with highly active disease and pre­
dictive of radiographic progression (12). However, comparison 
of these data with other cohorts that either support (13,14) or 
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refute (15–17) this notion is challenging due to a lack of consis­
tency in quantitative and qualitative assessment of B cell synovitis, 
the effects of concomitant diverse therapy, and examination of 
patients at variable disease stages and levels of disease activity.
Importantly, it remains unclear whether an association 
between B cell synovitis and disease severity is modulated during 
disease progression, and moreover, whether the prevalence of B 
cell synovitis remains stable or is enriched through disease evo­
lution and/or cycles of nonresponse to therapy. Since 2008, the 
Centre for Experimental Medicine and Rheumatology at Queen 
Mary University of London (QMUL) has been collecting pretreat­
ment synovial tissue as part of a pathobiology­ driven patient strat­
ification program in RA. This program includes patients enrolled 
in 2 multicenter precision­ medicine clinical studies collecting pre­
treatment synovial tissue at specific disease stages: untreated 
early RA (the Pathobiology of Early Arthritis Cohort [PEAC; http://
www.peac­mrc.mds.qmul.ac.uk]) and established RA in patients 
with an inadequate response to tumor necrosis factor inhibitors 
(TNFi­ IR) (Response–Resistance to Rituximab versus Tocilizumab 
in RA [R4RA; http://www.r4ra­nihr.whri.qmul.ac.uk]).
In this study, we developed and validated a semiquantitative 
scoring system focused on the measurement of B cell synovitis in 
RA. By analyzing the prevalence of B cell synovitis using a robust 
histologic score, we examined whether the association between 
B cell synovitis and clinical phenotype is a stable phenomenon 
during disease evolution or is enriched in a cohort of patients with 
treatment­ resistant established RA.
PATIENTS AND METHODS
Patients. A total of 329 patients fulfilling the 2010 American 
College of Rheumatology/European League Against Rheuma­
tism classification criteria for RA (18) were evaluated at 2 disease 
stages: early RA and established RA with an inadequate response 
to TNFi. The early RA cohort consisted of 165 consecutive patients 
with untreated early RA (disease duration <1 year) recruited as 
part of the Medical Research Council–funded multicenter PEAC. 
The established RA cohort consisted of 164 patients with an 
inadequate response to TNFi from the multicenter R4RA trial. The 
PEAC­ R4RA investigators are listed in Appendix A.
Synovial tissue specimens were obtained from all patients 
at study entry by ultrasound (US)–guided synovial biopsy (19) or 
arthroscopic approaches depending on the expertise of the local 
recruiting center. A minimum of 6 samples for subsequent histo­
logic analysis and 6 samples for RNA extraction were retained 
from each procedure. Patient demographic characteristics and 
clinical parameters collected at baseline included sex, disease 
duration, anti–citrullinated protein antibody (ACPA) and rheu­
matoid factor (RF) status, erythrocyte sedimentation rate (ESR), 
C­ reactive protein (CRP) level, swollen and tender joint counts, 
global health score (measured on a visual analog scale), and 
concomitant medications. All patients provided written informed 
 consent, and each study received local ethics approval (PEAC 
LREC: 05/Q0703/198; R4RA: LREC 12/WA/0307).
Semiquantitative histopathologic scoring and  digital 
image analysis. Formalin­ fixed and paraffin­ embedded synovial 
tissue sections (3 μm) were stained with hematoxylin and eosin 
(H&E) and semiquantitatively assessed for the degree of synovitis 
(on a scale of 0–9), according to a previously validated score (20). 
Consecutive sections were subjected to immunohistochemical 
staining for CD20 (mouse IgG2a anti­ human CD20) (clone L26; 
Dako), CD68 (mouse IgG1 anti­ human CD68) (clone KP1; Dako), 
and CD138 (mouse IgG1 anti­ human CD138) (clone MI15; Dako), 
as previously described (13). Slides were counterstained with 
hematoxylin and mounted. Images were acquired on an Olympus 
microscope using cellSens software.
First, the nature and quality of the tissue biopsy specimens 
were assessed by evaluating tissue morphology by H&E stain­
ing and macrophage distribution (CD68 staining). To be consid­
ered suitable for further histologic analysis, synovial samples had 
to present either a clear synovial lining (CD68+ cells in a linear 
arrangement) or sublining (characteristic vessels and stroma). 
Samples were rejected and classified as ungraded if there was 
no recognizable synovial tissue or there were artifactual changes 
(i.e., tissue folds, cutting and staining artifacts) in immunohisto­
chemical stainings. Samples with synovium were scored semi­
quantitatively (on a scale of 0–4) for the degree of CD20+ B cell 
infiltration, adapting a previously described B cell aggregation 
score (21) (Figures 1A and B). Patients were classified as B cell 
poor (semiquantitative score 0–1) or B cell rich (score 2–4), as 
shown in the flow chart in Supplementary Figure 1, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41184/ abstract. In B cell–poor samples, the 
presence of plasma cells was assessed, and samples with a semi­
quantitative CD138 score of ≥2 underwent an additional staining 
for CD20 at a deeper cutting level for a final classification as B 
cell poor or B cell rich. An overview of the cutting protocol at dif­
ferent levels is shown in Supplementary Figure 2, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41184/ abstract. All samples were assessed by 2 
independent observers.
For quantitative analysis using digital image analysis, whole 
CD20­ stained slides were reacquired using a Panoramic 250 High­ 
Throughput Scanner (3DHISTECH). Images were visualized and 
analyzed on Fiji software (22) using a pipeline developed in­ house 
(by DL) to obtain the following measurements: total stained area, 
total tissue area, and area fraction (percent of stained area, calcu­
lated as total stained area/total tissue area × 100). In the digital image 
analysis pipeline, the operator first manually selected region(s) of 
interest corresponding to the synovial tissue detectable on the slide 
(the “total tissue area”). The script then 1) removed the areas out­
side the region(s) of interest, 2) performed a color deconvolution to 
isolate the diaminobenzidine (DAB) color vector (method “H­ DAB”), 
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and 3) calculated the intensity threshold (method “Default,” manu­
ally adjusted if necessary) on the DAB channel. Finally, the software 
calculated the area included in the threshold (“total stained area”). 
An example of digital image analysis is shown in Supplementary 
Figure 3, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41184/ abstract.
In a pilot assessment exercise, digital image analysis was 
performed in parallel in a blinded manner by 2 observers from 
2 different centers (QMUL and University of Pavia). The analysis 
was performed on 15 random samples from the early RA PEAC 
cohort and replicated on the first 100 consecutive samples from 
the TNFi­ IR R4RA cohort in order to obtain independent measure­
ments. Intraclass correlation coefficients for the level of agreement 
between the 2 observers and Bland­ Altman plots were generated. 
Following this validation exercise, digital image analysis was per­
formed in the subset of patients from the early RA cohort who 
underwent RNA sequencing (n = 91) and in the patients in the 
TNFi­ IR cohort who had graded synovial tissue samples (n = 155).
RNA extraction and RNA sequencing. RNA extraction 
and RNA sequencing were performed as previously described 
(12) on synovial tissue samples from 94 patients in the early 
RA PEAC cohort and 128 patients in the TNFi­ IR R4RA cohort 
for whom RNA was available. For the PEAC cohort, RNA was 
extracted from synovial tissue homogenized at 4°C in TRIzol 
 reagent, according to the recommendations of the manufacturer 
(ThermoFisher Scientific, Invitrogen Division), followed by a phe­
nol–chloroform extraction. Briefly, the tissue lysate was mixed 
vigorously with chloroform before centrifugation. The aqueous 
phase was removed and mixed with ice­ cold isopropanol for 30 
minutes. After further centrifugation, the RNA pellet was washed 
in 70% ethanol before air­ drying and resuspension in RNase­ free 
water.
The concentration/purity of RNA samples was measured 
using a NanoDrop 2000c spectrophotometer (LabTech) and 
Qubit assay (ThermoFisher Scientific, Invitrogen Division). RNA 
quality (RNA integrity number) was assessed using an Agilent 
2100 Bioanalyzer or Agilent TapeStation system. One microgram 
of total RNA was used as input material for library preparation 
using a TruSeq RNA Sample Preparation Kit v2 (Illumina). Gener­
ated libraries were amplified with 10 cycles of polymerase chain 
reaction (PCR). The size of the libraries was confirmed using a 
2200 TapeStation system and High­ Sensitivity D1K ScreenTape 
(Agilent Technologies), and their concentration was determined by 
a quantitative PCR (qPCR)–based method using a Library Quan­
tification kit (KAPA). The libraries were first multiplexed (5 per lane) 
Figure 1. B cell scoring. A, Representative images for each semiquantitative CD20 immunohistochemical score in patients with rheumatoid 
arthritis with an inadequate response to tumor necrosis factor inhibitors. Bars = 500 μm. B, Higher­ magnification views of the boxed areas in 
A. Bars = 100 μm.
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and then sequenced on an Illumina HiSeq 2500 system to gener­
ate 50 million paired ends with 75 base pair reads.
For the R4RA cohort, the RNA extraction method was the 
same as for the PEAC, but subsequent to homogenization in TRI­
zol, a column­ based extraction (Zymo Direct­ zol RNA MicroPrep) 
was used according to the recommendations of the manufacturer 
for the majority of samples (n = 124), while phenol–chloroform 
extraction as described above was used on a small number of 
samples (n = 4). Principal components analysis confirmed that 
there were no major differences between the 2 extraction methods 
(data not shown). One hundred fifty to five hundred nanograms of 
total RNA was used as input material for library preparation using 
NEBNext Ultra RNA Library Prep Kit for Illumina according to the 
recommendations of the manufacturer (New England Biolabs). 
Generated libraries were amplified with 13 cycles of PCR. Library 
quality control was performed with MiSeq Nano QC, and the final 
concentration was determined by a qPCR­ based method using a 
Library Quantification kit. The libraries were first multiplexed and 
then sequenced on an Illumina HiSeq 4000 system to generate 
50 million paired ends with 150 base pair reads (Genewiz). A 
summary of the RNA extraction and sequencing methods for the 
2 cohorts is included in Supplementary Table 1, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41184/ abstract.
RNA sequencing analysis. For the PEAC cohort, tran­
script abundance was derived from fastq files over Gencode 
version24/GRCh38 transcripts using Kallisto version 0.43.0 (23). 
Transcript abundances and average transcript lengths were 
imported into R using tximport 1.10.0. Imported abundances 
were normalized in R, including a correction for average transcript 
length and incorporating batch, sex, and synovial histology pat­
terns (pathotypes) (12) as model covariates, using DESeq2 1.22.0 
(24). Transcript abundances underwent regularized log expression 
(RLE) transformation. The RNA­ Seq data have been deposited in 
the ArrayExpress database (online at https ://www.ebi.ac.uk/array 
express; accession no. E­ MTAB­ 6141). Outliers were identified 
and removed using principal components analysis, leaving 91 
samples for further analysis.
For the R4RA cohort, transcript abundance was quantified 
using Salmon version 0.12.0 (25) with the Gencode version 29/
GRCh38 annotation, and quantifications were aggregated to 
genes using tximport version 1.10.1. Data were subjected to 
variance­ stabilizing transformation to remove the dependency 
of the variance on the count mean using DESeq2 version 2.16.1 
(24). Outliers were identified and removed using principal compo­
nents analysis, leaving 127 samples for further analysis.
Definition of the B cell–specific gene module. Cell­ 
specific gene modules were obtained as previously described 
(26). Briefly, we downloaded RLE­ normalized FANTOM5 data 
from http://fantom.gsc.riken.jp/5/data/. Upon selecting primary 
cells and tissue and excluding derived cells, stimulated cells 
and cell line data were Z score–normalized, and the expression 
of each gene was ranked across all tissues and cells. A speci­
ficity score was determined by counting the number of tissues 
and cells showing increased gene expression (Z score >3 [>3 SD 
above the mean across all tissues]), so that the most tissue­ 
specific genes would have the lowest specificity scores. Genes 
were considered specific to a tissue type or cell type when: 1) the 
level of gene expression was in the top 3 tissues (i.e., rank 1–3); 
2) the Z score was >5 (i.e., >5 SD above the mean expression 
across all tissues); and 3) the specificity score was <10 tissues. 
Gene modules for different cell types were consistent with lists of 
genes previously published by the FANTOM5 consortium for sev­
eral cell types (27,28). The list of B cell–specific genes (B cell mod­
ule; including Z scores, specificity scores, and rank) is shown in 
Supplementary Table 2, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41184/ 
abstract.
Synovial RNA- Seq B cell module scores. The B cell 
module was used to calculate synovial RNA­ Seq B cell module 
scores, by applying singular value decomposition to synovial RNA­ 
Seq data (29). Briefly, the normalized gene expression matrix for 
the patients was filtered to include only the B cell module genes. 
Next, the matrix was subjected to singular value decomposition, 
and the first principal component score was taken as the module 
expression or “module score” for plotting. B cell module scores 
were analyzed for correlation against histologic markers in syno­
vial tissue using Spearman’s correlation.
Statistical analysis. Measures of central tendency and 
dispersion and statistical tests used are indicated in each figure 
legend. Generally, the following statistical tests were used: Mann­ 
Whitney test for comparison between 2 groups, one­ way analysis 
of variance with Bonferroni post hoc adjustment for comparison 
between multiple groups, chi­ square test for proportions, and 
Spearman’s test for correlations. Statistical analyses were per­
formed using IBM SPSS version 20 and RStudio version 0.99.486. 
P values less than 0.05 were considered significant.
RESULTS
Demographic and clinical features of the patients 
with early RA and those with established RA. A total of 329 
patients with RA were included in this study: 165 with untreated 
early RA (PEAC) and 164 with an inadequate response to TNFi 
(R4RA trial). Table 1 summarizes the patient characteristics. Both 
cohorts included patients with highly active RA (mean Disease 
Activity Score in 28 joints [DAS28] >5.1), with no differences in 
terms of disease activity (DAS28 and its components) and other 
clinical features, except for a higher prevalence of female patients, 
higher CRP levels, and higher proportion of ACPA­ positive 
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patients in the cohort with established RA. There were no differ­
ences between the cohorts with regard to the type of joint biop­
sied. Importantly, >70% of the samples were obtained from small 
joints (i.e., wrists or metacarpophalangeal joints), and >90% of the 
procedures were performed under US guidance. The procedures 
had an excellent success rate in terms of retrieval of gradable tis­
sue, ranging from 86.7% (143 of 165) in the early RA cohort to 
94.5% (155 of 164) in the TNFi­ IR cohort. These results demon­
strate that both the early RA and established RA cohorts included 
patients with active RA, although the patients with established RA 
showed more aggressive features, such as a greater proportion of 
patients with autoantibody positivity and higher levels of markers 
of inflammation, which is compatible with their recruitment after 
anti­ TNF failure.
Validation of semiquantitative synovial B cell scor-
ing by digital image analysis. To quantify the presence of B 
cells in synovia, we adapted a semiquantitative scoring method 
(scale of 0–4) previously described by our group (21). Repre­
sentative examples of tissue samples for each score are shown 
in Figures  1A and B, and a flow chart of the evaluation of the 
biopsy samples is shown in Supplementary Figure 1, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41184/ abstract. In order to validate the 
semiquantitative B cell scores against an objective measurement, 
we used computer­ aided automated digital image analysis. To this 
end, whole slide images were acquired, and digital image analysis 
was used to obtain the following measurements: total tissue area 
(in μm2), total stained area, and area fraction (percent of stained 
area, calculated as total stained area/total tissue area × 100). An 
example of the digital image analysis approach is shown in Sup­
plementary Figure 3, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41184/ 
abstract. First, we aimed to evaluate the reproducibility of digital 
image analysis, by performing the analyses in 2 different centers 
(QMUL and University of Pavia) in a blinded manner on 15 ran­
domly selected synovial samples from the early RA cohort and 
100 consecutive samples from the TNFi­ IR cohort. These analy­
ses showed an excellent agreement rate, with an intraclass cor­
relation coefficient of 0.97 in the early RA cohort (Figure 2A) and 
0.96 in the TNFi­ IR cohort (Figure 2B).
Having confirmed the reproducibility of digital image anal­
ysis, we next aimed to evaluate the correlation between the 
semiquantitative and digital image analysis (CD20+ area fraction) 
histologic B cell scores in 91 patients in the early RA cohort and 
164 patients in the TNFi­ IR cohort. Our results demonstrated 
a strong correlation between the semiquantitative and digital 
image analysis CD20 scores (Spearman’s r = 0.93 in the early RA 
cohort and 0.88 in the TNFi­ IR cohort; P < 0.0001) (Figures 2C 
and D). In addition, we determined the mean CD20+ area frac­
tion in patients classified as B cell rich and those classified as B 
cell poor according to the semiquantitative scores and demon­
strated a significantly higher CD20+ area fraction in B cell–rich 
patients, as shown in Figures 2E and F (mean ± SD area fraction 
1.4 ± 1.6 in B cell–rich patients and 0.02 ± 0.05 in B cell–poor 
patients in the early RA cohort [P < 0.0001] and 1.3 ± 1.9 in B 
cell–rich patients and 0.04 ± 0.1 in B cell–poor patients in the 
TNFi­ IR cohort [P < 0.0001]). Overall, our results demonstrate 
that the semiquantitative CD20 score presented both as a raw 
score and when applied to stratify patients into B cell–rich and B 
cell–poor cohorts reliably reflects quantitative measures of CD20 
B cell infiltration assessed using computer­ aided digital image 
analysis.
Table 1. Characteristics of the patients in the early RA and TNFi­IR 
cohorts*
Early RA 
(n = 165)
TNFi-IR 
(n = 164) P†
Age, years 53.2 ± 15.3 54.6 ± 13.3 NS
Sex, % female 66.1 79.9 0.005
Disease duration,  
years
0.5 ± 0.6 12.8 ± 10.8 <0.001
DAS28 5.7 ± 1.4 5.63 ± 1.27 NS
Tender joint count 11.6 ± 7.6 11.85 ± 7.8 NS
Swollen joint count 7.5 ± 5.6 6.92 ± 5.10 NS
Global health score 
(100- mm VAS)
61.5 ± 26.9 66.33 ± 24.99 NS
ESR, mm/hour 37.8 ± 28.4 34.47 ± 25.95 NS
CRP, mg/liter 17.6 ± 27.1 21.13 ± 27.97 0.01
ACPA positive, %‡ 64.2 75.3 0.03
RF positive, % 65.5 71.4 NS
No. of conventional 
synthetic 
DMARDs 
received, %
NA
0 100 2.4
1 0 67.7
2 0 21.3
3 0 8.4
Receiving steroids 
at the time of 
biopsy, % 
0 42.2 NA
Joint biopsied, % NS
Wrist 64.8 60.4
Knee 18.2 23.8
MCP 13.9 11
Other 3.1 4.8
Joint size, % NS
Large 25.2 27.4
Small 74.8 72.6
Synovial sampling 
technique, %
NA
US- guided 100 86
Arthroscopy 0 14
* Except where indicated otherwise, values are the mean ± SD. RA = 
rheumatoid arthritis; TNFi-IR = inadequate response to tumor 
necrosis factor inhibitors; NS = not significant; DAS28 = Disease 
Activity Score in 28 joints; VAS = visual analog scale; ESR = 
erythrocyte sedimentation rate; CRP = C- reactive protein; RF = 
rheumatoid factor; DMARDs = disease- modifying antirheumatic 
drugs; NA = not applicable; MCP = metacarpophalangeal; US = 
ultrasound. 
† By chi- square test or Mann- Whitney test. 
‡ Anti–citrullinated protein antibodies (ACPAs) were measured 
using a clinically available standard pathology laboratory anti–cyclic 
citrullinated peptide antibody 2 assay. 
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Correlation between semiquantitative and quantita-
tive histologic scores and B cell–lineage genes. Next, we 
evaluated the relationship between CD20+ B cell histologic scores 
(semiquantitative and digital image analysis) and B cell–specific 
gene expression levels. To this end, we correlated histologic scores 
for B cells with CD20 gene expression levels and RNA­ Seq B cell 
module scores obtained by RNA sequencing of synovial tissue from 
91 patients in the early RA cohort and 127 patients in the TNFi­ IR 
cohort. Our results demonstrated a strong correlation between 
the semiquantitative CD20 score and B cell module score and 
between the semiquantitative CD20 score and CD20 gene expres­
sion, both in the early RA cohort (Figure 3A) and the TNFi­ IR cohort 
(Figure 3B). Similarly, we observed a positive correlation between 
the digital image analysis CD20 area fraction and the B cell module 
score and between the digital image analysis CD20 area fraction 
and CD20 gene expression in the early RA cohort (Figure 3C) and 
the TNFi­ IR cohort (Figure 3D). Finally, when patients were seg­
regated into B cell–rich and B cell–poor subgroups, we demon­
strated significantly higher levels of B cell module scores and CD20 
gene expression in B cell–rich patients in both cohorts (Figures 3E 
and F). Overall, our results demonstrate that the semiquantitative 
CD20 score presented both as a raw score and when applied to 
stratify patients into B cell–rich and B cell–poor cohorts accurately 
reflects the levels of synovial B cell gene expression.
Clinical features of B cell–rich patients and B cell–poor 
patients at different disease stages. Next, we applied the 
semiquantitative CD20 score and algorithm shown in Figure 1 and 
Supplementary Figure 1 to stratify patients from the 2 cohorts into B 
cell–rich and B cell–poor categories. We assessed the prevalence 
of B cell–rich synovitis at different stages of disease evolution and 
drug exposure, i.e., in untreated early RA versus established RA with 
Figure 2. Semiquantitative (SQ) B cell scores and digital image analysis. A and B, Bland­ Altman plots showing the difference between and 
average of 2 measurements of CD20+ B cell area fraction (percent of stained area, calculated as total stained area/total tissue area × 100) 
in the cohort of patients with early rheumatoid arthritis (RA; n = 15) (A) and in the cohort of patients with established RA with an inadequate 
response to tumor necrosis factor inhibitors (TNFi­ IR; n = 100) (B), obtained by 2 independent observers in 2 different centers (Queen Mary 
University of London and University of Pavia). Solid lines indicate the mean; dotted lines indicate the 95% confidence interval. ICC = intraclass 
correlation coefficient. C and D, Correlation between semiquantitative CD20+ B cell score and CD20+ B cell area fraction in the early RA cohort 
(n = 91) (C) and the TNFi­ IR cohort (n = 155) (D). E and F, CD20+ B cell area fraction in the early RA cohort (n = 91) (E) and the TNFi­ IR cohort 
(n = 155) (F) classified as B cell poor or B cell rich. Symbols represent individual patients; horizontal lines and error bars show the mean ± SD. 
* = P < 0.05 by Mann­ Whitney test. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/
art.41184/abstract.
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an inadequate response to TNFi. Interestingly, we demonstrated a 
significantly higher prevalence of B cell–rich synovitis in patients 
with established RA with an inadequate response to TNFi (47.7% 
in the TNFi­ IR cohort and 35% in the untreated early RA cohort; 
P = 0.025) (Figure 4A), suggesting an increase in the  proportion of B 
cell–rich samples in longstanding treatment­ resistant RA.
Furthermore, we examined the relationship between clin­
ical phenotype and B cell–rich synovitis at each disease stage 
(Table 2). Consistent with previously published data (12), compared 
to B cell–poor patients, patients with B cell–rich synovitis in the 
early RA cohort showed higher levels of synovial inflammation, as 
measured by the Krenn synovitis score (P < 0.0001), which is a 
well­ validated composite score measuring the enlargement of the 
lining cell layer, the cellular density of synovial stroma, and leukocyte 
infiltrate. Accordingly, B cell–rich patients had significantly higher 
levels of other immune cells (T cells, macrophages, and plasma 
cells). Clinically, B cell–rich patients showed higher disease activ­
ity (P = 0.005 for DAS28 and P = 0.048 for swollen joint count), 
markers of inflammation (P = 0.001 for ESR and P = 0.012 for 
CRP level), and a higher prevalence of autoantibody positivity 
(P = 0.024 for ACPA and P = 0.023 for RF) than B cell–poor patients.
Conversely, in the cohort of patients with established disease 
(TNFi­ IR), while the significant association of B cell–rich synovitis 
with histologic synovitis and immune cell infiltration was maintained 
(Table 2 and Figure 4B), the only significant difference in terms of 
systemic inflammation or disease activity was a higher CRP level 
in B cell–rich patients than in B cell–poor patients (Table 2 and 
Figure 4C) (P = 0.001). There were no differences in terms of dis­
ease activity as measured by DAS28 (Figure 4D) and its compo­
nents (Table 2). Importantly, there were also no differences in the 
use of synthetic disease­ modifying antirheumatic drugs (DMARDs) 
or steroids between B cell–rich and B cell–poor patients. These 
data suggest that the clinical phenotype of highly active, aggres­
sive RA associated with a B cell–rich synovitis at disease initiation 
Figure  3. Correlation of semiquantitative (SQ) B cell scores with RNA­ Seq B cell module scores. A and B, Correlations between the 
semiquantitative CD20+ B cell score and the RNA­ Seq B cell module and between the semiquantitative CD20+ B cell score and CD20/MS4A1 
gene expression levels in the cohort of patients with early rheumatoid arthritis (RA) (A) and the cohort of patients with established RA with 
an inadequate response to tumor necrosis factor inhibitors (TNFi­ IR) (B). C and D, Correlations between the CD20+ B cell area fraction (AF) 
(percent of stained area, calculated as total stained area/total tissue area × 100) and the RNA­ Seq B cell module and between the CD20+ B 
cell area fraction and CD20/MS4A1 gene expression levels in the early RA cohort (C) and the TNFi­ IR cohort (D). In A–D, symbols represent 
individual patients (n = 91 for early RA and 127 for TNFi­ IR); Lines and shading indicate the regression line and 95% confidence interval. E and 
F, RNA­ Seq B cell module and CD20/MS4A1 gene expression levels in B cell–poor and B cell–rich patients in the early RA cohort (n = 91) (E) 
and TNFi­ IR cohort (n = 127) (F). Symbols represent individual patients; horizontal lines show the mean. * = P < 0.05 by Mann­ Whitney test. 
Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41184/abstract.
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is subsequently lost with disease progression and/or modulation 
of synovial pathobiology by concomitant therapy.
To further explore the association of synovial histopathology 
with clinical phenotypes, we compared clinical features in patients 
classified according to semiquantitative scores for T cells, mac­
rophages, and plasma cells (Supplementary Tables 3–6, avail­
able on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41184/ abstract). In the early RA 
cohort, higher levels of markers of inflammation were observed in 
patients with higher infiltration of all immune cells. On the contrary, 
a higher prevalence of autoantibody positivity was observed only 
in patients who, in addition to B cells, were rich in synovial T cells 
and plasma cells, but no relationship was observed with CD68L 
or CD68SL macrophage populations. Notably, on the other hand, 
higher disease activity measured by DAS28 was present only 
in patients with higher sublining macrophages and plasma cell 
infiltration. In the cohort of patients with established RA, patients 
with synovitis rich in T cells, sublining macrophages, and plasma 
cells showed significantly higher CRP levels, while there were no 
differences in any other clinical parameter. These data add new 
insights into the association of immune cells with specific disease 
features, while confirming a lack of association between synovitis 
and clinical phenotypes in the cohort of patients with established 
RA.
DISCUSSION
In this study, we explored the prevalence and relationship to 
clinical phenotypes of B cell synovitis in a large, well­ characterized 
cohort of 329 patients at 2 different stages of disease evolution 
and drug exposure. We validated and applied a semiquantitative 
B cell synovitis score that accurately reflects quantitative mea­
sures of both cellular and molecular B cell infiltrate, and demon­
strated that the prevalence of B cell synovitis was enriched in 
patients with treatment­ resistant established disease. Addition­
ally, although patients with established RA display a more severe 
clinical phenotype, which could explain the enrichment in B cells, 
we observed that the significant association of a B cell–rich syno­
vitis with a clinical phenotype of highly active aggressive RA in 
untreated early disease was diluted at later stages.
Previous data have suggested that ~40% of RA patients 
present synovitis characterized by a B cell–rich infiltrate, both in 
early (9–11) and late­ stage disease (6). However, the clinical rele­
vance of B cell synovitis has been a subject of controversy, with 
Figure 4. B cell–rich synovitis at different rheumatoid arthritis (RA) disease stages. A, Prevalence of B cell–rich synovitis in the cohort of 
patients with early RA and in the cohort of patients with established RA with an inadequate response to tumor necrosis factor inhibitors (TNFi­ 
IR). B–D, Krenn synovitis score (B), C­ reactive protein (CRP) level (C), and Disease Activity Score in 28 joints (DAS28) using the erythrocyte 
sedimentation rate (D) in B cell–poor and B cell–rich patients in the early RA cohort and the TNFi­ IR cohort. Symbols represent individual 
patients (n = 143 for early RA and 155 for TNFi­ IR); horizontal lines and error bars show the median and interquartile range in B and the 
mean ± SD in C and D. * = P < 0.05 by chi­ square test in A; by Mann­ Whitney test in B–D. NS = not significant.
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previous reports presenting conflicting data on the relationship of 
B cell synovitis with clinical phenotype (15–17). We attempted to 
overcome the limitations presented by previous analyses (30,31) 
by implementing a consistent and validated semiquantitative B 
cell score. This score was shown to be a reliable measure of total 
B cell content by validation against objective histologic and molec­
ular quantitative measurements (digital image analysis and RNA­ 
Seq transcript lineage analysis, respectively) in large, well­ defined 
cohorts of patients. Although the validation of semiquantitative 
histologic synovial T cell and macrophage scores using digital 
image analysis has been explored previously (32,33), validation 
of semiquantitative CD20 scores against both digital image anal­
ysis and B cell–lineage transcript analysis has not. In particular, 
the evaluation against B cell transcripts represents an invaluable 
confirmation that the semiquantitative histologic score used to 
grade limited tissue sections accurately reflects the B cell content 
of the whole specimen (6 additional biopsy specimens pooled for 
RNA extraction), therefore representing a reliable method for the 
assessment of B cells in synovia.
The significant association of B cell–rich synovitis with highly 
active seropositive RA in untreated early disease supports previ­
ous observations (12) and suggests that synovial tissue cellular 
infiltration could help define histologic RA subsets, similarly to what 
has been described for seronegative and seropositive RA (34). 
Consistent with these observations, the presence of B cell–rich 
lymphoid aggregates in early RA has recently been shown to pre­
dict treatment response to conventional synthetic DMARDs and 
radiographic progression (12) and to enhance clinical classification 
and prognostic/treatment response algorithms (35). In established 
RA, the associations of B cell synovitis with local inflammation 
(histologic synovitis) and CRP persisted, and patients showed a 
more aggressive clinical phenotype overall, but there was a lack of 
association of B cell–rich synovitis with clinical markers of disease 
activity such as the DAS28. This lack of association suggests that 
current standard clinimetric assessment of disease activity may 
be too insensitive to detect ongoing histologic inflammation, as 
it might be confounded by factors such as concomitant therapy 
or comorbidities and their impact on patient­ reported outcomes 
and disease activity scores. To overcome such limitations, future 
analyses may include alternative measures of disease activity, 
including, for example, the reweighted 2­ component imaging­ 
derived disease activity score (36), and determine their relation­
ship with histologic synovitis. To date, in fact, very little is known 
about the association of histologic synovitis with clinical pheno­
types. Importantly, our observations could provide an explanation 
for the variable associations observed between clinical phenotype 
Table 2. Clinical phenotype of B cell–poor versus B cell–rich patients at different RA disease stages*
Early RA 
(n = 143)
TNFi-IR 
(n = 155)
B cell poor  
(n = 93 [65.0%])
B cell rich  
(n = 50 [35.0%]) P†
B cell poor  
(n = 81 [52.3%])
B cell rich  
(n = 74 [47.7%]) P†
DAS28 5.6 ± 1.38 6.1 ± 1.2 0.005 5.6 ± 1.3 5.7 ± 1.2 NS
Tender joint count 11.3 ± 7.3 13 ± 7.7 NS 12.5 ± 7.9 11.2 ± 7.8 NS
Swollen joint count 7.1 ± 5.4 8.8 ± 5.7 0.048 6.5 ± 5.1 7.4 ± 5.1 NS
Global health score  
(100- mm VAS)
60.6 ± 28.6 64.8 ± 25.2 NS 65.2 ± 23.2 66.8 ± 27.3 NS
ESR, mm/hour 34.6 ± 28.9 49.5 ± 28.9 0.001 31.7 ± 24.4 38.3 ± 27.2 NS
CRP, mg/liter 17.5 ± 32.7 21.5 ± 24.2 0.012 19.9 ± 35.9 26.4 ± 26.8 0.001
ACPA positive, %‡ 59.8 78.4 0.024 73.1 76.4 NS
RF positive, % 62 80.4 0.023 70 72.2 NS
No. of conventional synthetic 
DMARDs received, %
NA NS
0 100 100 1.2 4.1
1 0 0 70.4 67.6
2 0 0 21 23
3 0 0 7.4 5.4
Receiving steroids at the time 
of biopsy, %
0 0 NA 39.7 41.9 NS
Synovitis score 3 ± 1 6 ± 1 <0.0001 2 ± 2 6 ± 2 <0.0001
Semiquantitative CD3  
score ≥2, %
6.5 70.8 <0.0001 9.1 90.9 <0.0001
Semiquantitative CD68L 
score ≥2, %
12.2 46 <0.0001 6.2 93.8 <0.0001
Semiquantitative CD68SL 
score ≥2, %
24.2 84 <0.0001 17.1 82.9 <0.0001
Semiquantitative CD138 
score ≥2, %
4.4 78 <0.0001 9.3 90.7 <0.0001
* Patients with ungraded synovial biopsy samples were excluded. Except where indicated otherwise, values are the mean ± SD. CD68L = CD68 
lining; CD68SL = CD68 sublining (see Table 1 for other definitions). 
† By Mann- Whitney test or Fisher’s exact test. 
‡ ACPAs were measured using a clinically available standard pathology laboratory anti–cyclic citrullinated peptide antibody 2 assay. 
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and synovial pathobiology in other disease cohorts where patients 
with varying disease duration and/or therapies were analyzed 
together (15,17).
Such disconnect between ongoing synovial inflammation and 
clinical disease activity could explain the reported radiographic 
progression in RA patients with low disease activity treated with 
synthetic and/or biologic DMARDs (37). However, future analyses, 
including the outcome of the R4RA trial, will help us to under­
stand whether B cell synovitis continues to drive radiographic 
progression in late­ stage disease, as recently demonstrated in 
early disease (12), and to further dissect the association of clinical 
parameters with histologic synovitis. An alternative explanation for 
such disconnect could be that different pathogenic mechanisms 
drive local synovial inflammation in early RA and in established RA 
and manifest different levels of clinical synovitis. For example, T 
cell cytokine signatures described in early RA do not appear to be 
present in later stages (38), while different immune cell infiltration 
has been found in synovial samples from patients with active RA 
compared with samples from patients with end­ stage destructive 
RA obtained at joint replacement (39). Importantly, however, our 
cohort of patients with established RA did not include patients 
with end­ stage RA, and the enriched B cell infiltrate in this cohort 
suggests that adaptive immunity continues to play a pivotal role in 
active established RA. Nonetheless, alternative non–B cell–driven 
synovitis may be present in different patients.
This study has some limitations. First, while we have ana­
lyzed 2 large cohorts of patients characterized by specific dis­
ease stages and drug exposure, our results do not include data 
on sequential biopsy or longitudinal clinical outcomes. Such data 
will emerge following completion of the R4RA trial and will be crit­
ical to determine whether our observation of an enrichment of B 
cell synovitis in patients with an inadequate response to TNFi is a 
treatment effect or is related to a propensity for B cell–rich patients 
to fail to respond to TNFi therapy.
Second, synovial sampling was performed by both US­ 
guided methods and arthroscopy, which could be considered a 
confounding factor due to the heterogeneity of sample retrieval 
methods and/or patient selection. However, recent data have 
shown an equivalence in quality outcomes of arthroscopy and 
US­ guided approaches (40). Moreover, the use of US­ guided 
biopsy for the majority of the procedures ensured that patients 
were included in the studies irrespective of joint distribution, a fac­
tor that is likely to account for the difference in results compared to 
previous studies that used only large joint arthroscopy (15), which 
is known to bias recruitment to patients with more severe disease 
(41), particularly in early RA.
Finally, we acknowledge that many other immune cells play 
a role in RA synovitis, driving both disease activity and progres­
sion and treatment response (42–44). We found that B cell infil­
tration was accompanied by T cells, sublining macrophages, and 
plasma cells, which is consistent with previously reported data 
(12). However, when comparing the clinical parameters in the 
early RA cohort, we observed that higher levels of markers of 
inflammation were associated with higher scores for all immune 
cells, but that a higher prevalence of autoantibody positivity was 
associated exclusively with higher B cell, T cell, and plasma cell 
scores. Higher disease activity was associated with higher B cell, 
sublining macrophage, and plasma cell scores. In the cohort of 
patients with established RA, these additional analyses confirmed 
the exclusive association of CRP levels with synovitis, without 
differences in any other parameters, once again suggesting that 
standard clinimetrics seems unable to pick up ongoing synovitis 
in established RA.
Overall, these data provide insights into the specific associa­
tions of immune cells with clinical phenotypes and highlight the rel­
evance of B cells as markers of ongoing synovitis associated with 
a clinical phenotype of aggressive disease in early RA. However, 
alternative histologic scoring systems that aim to more compre­
hensively assess immune cell infiltration are available, including an 
integrated histologic scoring system (10,12) that we have recently 
developed and that has been verified by combined histologic and 
­ omics approaches (11,45). Although it is likely that in the near 
future integrated histologic and molecular analyses will identify 
novel or previously unrecognized pathways mediating treatment 
response or resistance, in order to translate those studies to rou­
tine clinical care there is a need for well­ validated histopathologic 
scores that can be easily applied for patient classification, such 
as the B cell synovitis score described herein, particularly if it 
were demonstrated to have clinical utility for stratifying patients to 
receive rituximab.
In conclusion, we described the application of a robust, val­
idated B cell synovitis score that closely replicates the quantifi­
cation of B cells using either digital image analysis or RNA­ Seq 
analysis and identifies a significant enrichment of B cell synovitis in 
end­ stage treatment­ resistant RA. Furthermore, we demonstrated 
a variable association between B cell synovitis and clinical disease 
activity measurements at different stages of disease progression 
and drug exposure. In particular, the presence of synovial B cells 
in established treatment­ resistant RA helps identify patients with 
ongoing synovial inflammation that is not detected by standard 
clinimetric assessment. Overall, our study confirms the relevance 
of synovial B cells in RA and suggests that the classification of 
patients into B cell rich or B cell poor can contribute to patient 
stratification.
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APPENDIX A: THE PEAC- R4RA INVESTIGATORS
The PEAC­ R4RA investigators are as follows: Iain B. McInnes, Chris 
Buckley, Peter C. Taylor, Ernest Choy, Arthur Pratt, Christopher Edwards, 
Maya Buch, Nagui Gendi, Pauline Ho, Bhaskar Dasgupta, Patrick Durez, 
João Eurico Fonseca, Pier Paolo Sainaghi, Mattia Bellan, John Isaacs, 
Juan D. Cañete, Alberto Cauli, Mattia Congia, Piero Reynolds, Robert 
Moots, Nora Ng, Carlomaurizio Montecucco, and Patrick Verschueren.
